Your browser doesn't support javascript.
loading
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial.
Kim, Hyung-Don; Jung, Seyoung; Lim, Ho Yeong; Ryoo, Baek-Yeol; Ryu, Min-Hee; Chuah, Samuel; Chon, Hong Jae; Kang, Beodeul; Hong, Jung Yong; Lee, Han Chu; Moon, Deok-Bog; Kim, Ki-Hun; Kim, Tae Won; Tai, David; Chew, Valerie; Lee, Jeong Seok; Finn, Richard S; Koh, June-Young; Yoo, Changhoon.
Afiliação
  • Kim HD; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Jung S; Genome Insight, Inc., San Diego, La Jolla, CA, USA.
  • Lim HY; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
  • Ryoo BY; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Ryu MH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Chuah S; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Chon HJ; Translational Immunology Institute, SingHealth-Duke-NUS Academic Medical Centre, Duke-NUS Medical School, Singapore, Singapore.
  • Kang B; Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.
  • Hong JY; Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.
  • Lee HC; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Moon DB; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Kim KH; Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Kim TW; Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Tai D; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Chew V; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
  • Lee JS; Translational Immunology Institute, SingHealth-Duke-NUS Academic Medical Centre, Duke-NUS Medical School, Singapore, Singapore.
  • Finn RS; Genome Insight, Inc., San Diego, La Jolla, CA, USA.
  • Koh JY; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
  • Yoo C; Division of Hematology-Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Nat Med ; 30(3): 699-707, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38374347
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Piridinas / Carcinoma Hepatocelular / Neoplasias Hepáticas Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Piridinas / Carcinoma Hepatocelular / Neoplasias Hepáticas Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article